Medipal Holdings Corporation (JP:7459)
:7459
Want to see JP:7459 full AI Analyst Report?
Top Page
Medipal Holdings
(7459)
Select Model
Select Model
Rating:69Neutral
Price Target:
¥2,993.00
▲(5.13% Upside)
Action:Reiterated
Date:05/15/26
The score is driven primarily by strong financial stability (very low leverage and steady revenue growth) and supportive valuation (low P/E with a solid dividend yield). These positives are tempered by weaker technical momentum (below key moving averages with negative MACD) and some cash flow variability alongside thin margins.
Positive Factors
Conservative Balance Sheet
Very low leverage preserves financial flexibility, reduces bankruptcy risk, and enables investment in logistics, inventory and M&A. Rising equity from ~523B (2021) to ~652B (2026) strengthens the capital base, supporting long-term distribution scale and resilience against cyclical pressures.
Negative Factors
Thin Net Margins
Structural net margins near 1% leave little buffer for input cost inflation, pricing pressure, or reimbursement changes. Low margins constrain the firm's ability to self-fund large strategic initiatives and make earnings volatile relative to small swings in procurement or selling prices over coming quarters.
Read all positive and negative factors
Positive Factors
Negative Factors
Conservative Balance Sheet
Very low leverage preserves financial flexibility, reduces bankruptcy risk, and enables investment in logistics, inventory and M&A. Rising equity from ~523B (2021) to ~652B (2026) strengthens the capital base, supporting long-term distribution scale and resilience against cyclical pressures.
Read all positive factors
Medipal Holdings (7459) vs. iShares MSCI Japan ETF (EWJ)
Market Cap
¥514.12B
Dividend Yield2.27%
Average Volume (3M)365.88K
Price to Earnings (P/E)14.2
Beta (1Y)0.49
Revenue Growth3.98%
EPS Growth7.00%
CountryJP
Employees13,075
SectorHealthcare
Sector Strength45
IndustryMedical - Distribution
Share Statistics
EPS (TTM)196.37
Shares Outstanding215,975,040
10 Day Avg. Volume365,940
30 Day Avg. Volume365,883
Financial Highlights & Ratios
PEG Ratio2.04
Price to Book (P/B)0.93
Price to Sales (P/S)0.16
P/FCF Ratio15.14
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
¥2,700.00Price Target Upside-5.16% Downside
Rating ConsensusHold
Number of Analyst Covering1
EPS Forecast (FY)188.54
Revenue Forecast (FY)¥3.89T
Medipal Holdings Business Overview & Revenue Model
Company Description
Medipal Holdings Corporation engages in the prescription pharmaceutical wholesale business in Japan. It procures healthcare products related to diagnostics, testing, treatment, and administration comprises medical equipment and medical materials, ...
How the Company Makes Money
Medipal Holdings makes money primarily through wholesale distribution margins and related service fees earned by its operating subsidiaries. The core revenue stream is the sale of pharmaceuticals and other healthcare products purchased from manufa...
Medipal Holdings Financial Statement Overview
Summary
Income Statement
67
Positive
Balance Sheet
86
Very Positive
Cash Flow
63
Positive
| Breakdown | TTM | Mar 2026 | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 3.71T | 3.82T | 3.67T | 3.56T | 3.36T | 3.29T |
| Gross Profit | 244.32B | 247.41B | 242.25B | 233.01B | 212.12B | 205.11B |
| EBITDA | 74.89B | 81.38B | 74.03B | 65.31B | 63.62B | 59.96B |
| Net Income | 40.86B | 42.53B | 40.28B | 41.48B | 38.81B | 29.42B |
Balance Sheet | ||||||
| Total Assets | 1.85T | 1.92T | 1.82T | 1.80T | 1.70T | 1.71T |
| Cash, Cash Equivalents and Short-Term Investments | 246.03B | 289.07B | 261.41B | 230.47B | 195.03B | 261.92B |
| Total Debt | 38.85B | 0.00 | 4.17B | 1.46B | 7.38B | 38.81B |
| Total Liabilities | 1.09T | 1.13T | 1.07T | 1.06T | 1.02T | 1.06T |
| Stockholders Equity | 616.58B | 652.17B | 619.57B | 600.35B | 561.36B | 530.30B |
Cash Flow | ||||||
| Free Cash Flow | 0.00 | 39.93B | 51.70B | 46.28B | 5.66B | 45.26B |
| Operating Cash Flow | 0.00 | 46.55B | 60.56B | 61.84B | 16.15B | 61.22B |
| Investing Cash Flow | 0.00 | 9.30B | -3.36B | -7.82B | -39.47B | -24.34B |
| Financing Cash Flow | 0.00 | -29.40B | -25.95B | -25.25B | -43.56B | -16.47B |
Medipal Holdings Technical Analysis
Positive
2847.00
Price Trends
2849.61
Positive
2844.90
Positive
2703.36
Positive
Market Momentum
-11.58
Negative
59.00
Neutral
67.81
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:7459, the sentiment is Positive. The current price of 2847 is above the 20-day moving average (MA) of 2794.38, below the 50-day MA of 2849.61, and above the 200-day MA of 2703.36, indicating a bullish trend. The MACD of -11.58 indicates Negative momentum. The RSI at 59.00 is Neutral, neither overbought nor oversold. The STOCH value of 67.81 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for JP:7459.
Medipal Holdings Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
71 Outperform | ¥301.20B | 10.88 | 8.60% | 1.60% | 3.61% | 20.83% | |
69 Neutral | ¥514.12B | 14.22 | 6.39% | 2.27% | 3.98% | 7.00% | |
68 Neutral | ¥435.07B | 14.57 | 11.37% | 3.04% | 5.08% | 2.07% | |
67 Neutral | ¥358.08B | 16.82 | ― | 0.41% | 14.59% | 7.84% | |
66 Neutral | ¥423.73B | 11.01 | 6.92% | 2.69% | 4.83% | 56.24% | |
66 Neutral | ¥563.64B | 17.44 | 15.71% | 0.96% | 15.07% | 72.98% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
* Healthcare Sector Average
JP:7459
Medipal Holdings
2,834.00
638.43
29.08%
JP:2784
Alfresa Holdings
2,220.50
356.13
19.10%
JP:9989
Sundrug Co
3,721.00
-652.42
-14.92%
JP:7649
Sugi Holdings Co
2,990.50
-40.50
-1.34%
JP:9987
Suzuken Co
5,306.00
193.59
3.79%
JP:3549
KUSURI NO AOKI HOLDINGS CO.,LTD.
3,745.00
423.78
12.76%
Medipal Holdings Corporate Events
Medipal Lifts Year-End Dividend, Boosts Payout to Shareholders
May 14, 2026
Medipal Holdings has approved a higher year-end dividend of ¥34 per share for the fiscal year ended March 31, 2026, up from its prior forecast of ¥32 and above the previous year’s ¥32, bringing total annual dividends to ¥...
Medipal Posts Higher Sales and Profits, Lifts Dividend but Guides to Softer Earnings
May 14, 2026
Medipal Holdings reported a 4.0% rise in consolidated net sales to ¥3.82 trillion for the year ended March 31, 2026, while operating profit slipped 4.4% to ¥53.2 billion but ordinary profit climbed 16.0% to ¥75.7 billion on stronger...
Medipal Raises Year-End Dividend, Lifts Annual Payout to ¥66 Per Share
May 14, 2026
Medipal Holdings has announced an increase in its year-end dividend for the fiscal year ended March 31, 2026, raising the payout to ¥34 per share from the previously forecast ¥32, bringing total annual dividends to ¥66 per share inc...
Medipal Posts Higher Sales and Profit, Lifts Dividend but Guides Cautiously for FY2027
May 14, 2026
Medipal Holdings reported a 4.0% rise in consolidated net sales to ¥3.82 trillion for the fiscal year ended March 31, 2026, while operating profit slipped 4.4% to ¥53.2 billion but ordinary profit climbed 16.0% and profit attributable to...
Medipal Launches Tender Offer to Fully Acquire Paltac
May 11, 2026
Medipal Holdings’ board has approved a tender offer to acquire all remaining common shares of Paltac Corporation that it does not already own, at a price of ¥6,650 per share, between May 12 and July 7, 2026. The company currently holds ...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.